Home » Stocks » ADXS

Advaxis, Inc. (ADXS)

Stock Price: $0.767 USD -0.063 (-7.58%)
Updated Mar 3, 2021 4:00 PM EST - Market closed
After-hours: $0.759 -0.008 (-1.04%) Mar 3, 7:58 PM
Market Cap 85.88M
Revenue (ttm) 253,000
Net Income (ttm) -26.47M
Shares Out 61.00M
EPS (ttm) -0.43
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 3
Last Price $0.767
Previous Close $0.830
Change ($) -0.063
Change (%) -7.58%
Day's Open 0.832
Day's Range 0.745 - 0.835
Day's Volume 9,140,545
52-Week Range 0.264 - 1.570

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 month ago

Enrolling strategic expansion of ADXS-503 HOT program in NSCLC to explore potential to enhance and/or restore sensitivity to checkpoint inhibitors

GlobeNewsWire - 1 month ago

Non-dilutive capital strengthens balance sheet to further advance ADXS-HOT neoantigen program Non-dilutive capital strengthens balance sheet to further advance ADXS-HOT neoantigen program

GlobeNewsWire - 2 months ago

PRINCETON, N.J., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy produc...

Newsfile Corp - 2 months ago

New York, New York--(Newsfile Corp. - December 16, 2020) - Levi & Korsinsky announces it has commenced an investigation of Advaxis, Inc. (NASDAQ: ADXS) concerning possible breaches of fiduciar...

GlobeNewsWire - 3 months ago

PRINCETON, N.J., Nov. 27, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immu...

Insider Monkey - 3 months ago

Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 817 active prominent money managers and anal...

Benzinga - 3 months ago

Alnylam Pharmaceuticals (NASDAQ: ALNY) shares are trading higher on Tuesday after the company announced its OXLUMO injection has received FDA approval for the treatment of primary hyperoxaluri...

Other stocks mentioned: ALNY, ARWR
GlobeNewsWire - 3 months ago

PRINCETON, N.J., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immu...

GlobeNewsWire - 3 months ago

PRINCETON, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immu...

GlobeNewsWire - 3 months ago

Disease control rate of 67% and overall response rate of 17% in first six evaluable patients with immediate prior progression on KEYTRUDA ®

GlobeNewsWire - 4 months ago

PRINCETON, N.J., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Advaxis , Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy produ...

GlobeNewsWire - 5 months ago

PRINCETON, N.J., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy pro...

GlobeNewsWire - 5 months ago

Strategic transition to Investigator sponsored IND from previously announced Advaxis sponsored IND

GlobeNewsWire - 5 months ago

Strategic expansion of ADXS-503 HOT program in NSCLC to explore potential to enhance and or restore sensitivity to checkpoint inhibitors

GlobeNewsWire - 5 months ago

PRINCETON, N.J., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy pro...

GlobeNewsWire - 6 months ago

PRINCETON, N.J., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy prod...

GlobeNewsWire - 7 months ago

PRINCETON, N.J., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy prod...

GlobeNewsWire - 8 months ago

PRINCETON, N.J., June 23, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy prod...

Seeking Alpha - 8 months ago

Advaxis, Inc. (ADXS) CEO Ken Berlin on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 8 months ago

Expanding Phase 1/2 Study of ADXS-503 in NSCLC based on sustained and durable clinical responses in first two patients from Part B combination arm with KEYTRUDA®

GlobeNewsWire - 9 months ago

Sustained clinical benefit seen in patients treated with ADXS-503 in combination with KEYTRUDA® after 16 weeks, including a partial response and stable disease in patients who had most recentl...

Seeking Alpha - 11 months ago

Advaxis Is One Biotech That Should Be On Your Radar; Targeting Large NSCLC And Prostate Cancer Drug Markets

GlobeNewsWire - 1 year ago

First two patients treated in the combination arm who previously progressed on KEYTRUDA® showed substantial tumor shrinkage with ADXS-503 treatment in combination with KEYTRUDA®

GlobeNewsWire - 1 year ago

PRINCETON, N.J., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of im...

Seeking Alpha - 1 year ago

Advaxis, Inc. (ADXS) CEO Kenneth Berlin on Q2 2019 Results - Earnings Call Transcript

Benzinga - 1 year ago

Nanocap Advaxis, Inc. is seeing strength Wednesday following an announcement concerning its cervical cancer drug.

Zacks Investment Research - 1 year ago

Advaxis (ADXS) closed the most recent trading day at $3.29, moving -0.3% from the previous trading session.

Zacks Investment Research - 1 year ago

Is (ADXS) Outperforming Other Medical Stocks This Year?

The Motley Fool - 1 year ago

Equity offerings played a big role for two of these companies.

Benzinga - 1 year ago

Here's a roundup of top developments in the biotech space over the last 24 hours.

Other stocks mentioned: ADMA, NVS, RHHBY
Market Watch - 1 year ago

Shares of Advaxis Inc. plummeted 25% to pace all premarket declines Wednesday, after the biotechnology company's public offering of shares priced at a deep discount.

The Motley Fool - 1 year ago

The small-cap biotech reported encouraging news about its prostate cancer therapy.

Benzinga - 1 year ago

Advaxis, Inc. has announced a reverse stock split and clinical trial updates at the American Association of Cancer Research annual meeting in recent days.

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor in Advaxis.

Zacks Investment Research - 1 year ago

This owner and operator of a late-stage biotechnology company has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 64.7% over th...

Zacks Investment Research - 1 year ago

Is (ADXS) Outperforming Other Medical Stocks This Year?

About ADXS

Advaxis, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies... [Read more...]

Industry
Biotechnology
Founded
2002
CEO
Kenneth Berlin
Employees
17
Stock Exchange
NASDAQ
Ticker Symbol
ADXS
Full Company Profile

Financial Performance

In 2020, Advaxis's revenue was $253,000, a decrease of -98.79% compared to the previous year's $20.88 million. Losses were -$26.47 million, 59.3% more than in 2019.

Financial Statements